Exclusive Summary

• Offers the unique clinical benefit of "conscious sedation without respiratory depression," being a mandated first-line ICU sedative in international guidelines, highly aligned with the standard 1ml:0.1mg/2ml:0.2mg global presentation.
• Leverages China's highly vertically integrated "API + FDF" supply chain to guarantee robust, long-term, and geopolitically stable commercial supply for overseas distributors.
• Targets an inelastic global market driven by over 300 million major surgeries annually and a vast base of ICU admissions, with massive generic substitution potential in emerging markets like LATAM, MENA, and SEA.
• Provides aggressive cost competitiveness backed by comprehensive CTD dossiers, directly empowering foreign distribution partners to rapidly win local public hospital tenders and maximize profit margins.